证券代码：688622 证券简称：禾信仪器 公告编号：2023-049 广州禾信仪器股份有限公司 关于参加2022年度医疗设备专场集体业绩说明会 暨2023年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议线上交流时间：2023 年 6 月 16 日(星期五) 14:00-15:00 会议召开方式：视频和线上文字互动 视 频 和 线 上 文 字 互 动 平 台 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （http://roadshow.sseinfo.com/） 投资者可于 2023 年 6 月 15 日(星期四) 16:00 前通过邮件、电话、传真 等形式将需要了解和关注的问题提前提供给公司。公司将在文字互动环节对投资 者普遍关注的问题进行回答。 广州禾信仪器股份有限公司（以下简称"公司"）已于2023年4月26日发布公 司2022年年度报告及2023年第一季度报告，为便于广大投资者更全面深入地了解公 司2022年度及2023年第一季度经营成果、财务状况、发展理 ...

Financial Performance - The company reported a profit distribution plan for 2022, proposing not to distribute cash dividends, issue bonus shares, or convert reserves into share capital [6]. - The company has not achieved profitability since its listing [4]. - The company reported a total revenue of RMB 1.75 billion for the fiscal year 2022, reflecting a year-over-year growth of 15% [12]. - In 2022, the company's operating revenue was CNY 280.26 million, a decrease of 39.63% compared to CNY 464.24 million in 2021 [22]. - The net loss attributable to shareholders was CNY -63.33 million in 2022, a decline of 180.60% from a profit of CNY 78.57 million in 2021 [23]. - The basic earnings per share for 2022 was CNY -0.90, down 165.22% from CNY 1.38 in 2021 [24]. - The cash flow from operating activities was CNY -84.58 million in 2022, a decline of 666.56% from CNY 14.93 million in 2021 [23]. - The company achieved a total annual signed contract amount of CNY 51.39 million, representing a year-on-year growth of 18.05%, while annual revenue decreased by 39.63% to CNY 28.03 million [32]. - The company reported a significant decline in net profit, shifting from profit to a loss of CNY 6.33 million compared to the previous year [32]. Research and Development - The company is investing in R&D, with a budget allocation of RMB 200 million, representing 11% of total revenue [12]. - Research and development expenses accounted for 27.73% of operating revenue in 2022, up from 11.31% in 2021 [25]. - The total R&D investment for the year was approximately ¥77.70 million, a 47.97% increase from the previous year's ¥52.51 million [77]. - The company has accumulated 50 domestic invention patents and 91 utility model patents by the end of the reporting period [34]. - The company is focusing on expanding its market presence in environmental monitoring, particularly in air quality monitoring and industrial park toxic substance monitoring [33]. - The company is actively exploring new business models in various application scenarios, including microbial diagnostics and food safety [35]. - The company has developed key components such as the electrospray ion source and time-of-flight mass analyzer, enhancing its competitive advantage [90]. - The company is focusing on the development of mass spectrometers, which are categorized as intelligent measurement and control equipment, aligning with national strategic emerging industries such as electronic information and new materials [69]. Market Expansion and Strategy - The company expects revenue growth to continue in 2023, projecting an increase of 10% to 12% [12]. - Market expansion efforts are underway, targeting Southeast Asia, with an expected market entry by Q3 2023 [12]. - The company is exploring potential acquisitions to enhance its product portfolio, with a focus on companies specializing in environmental monitoring technologies [12]. - The company plans to enhance its online sales channels, aiming for a 30% increase in e-commerce revenue by the end of 2023 [12]. - The company aims to enhance its core competitiveness and increase its market share in the domestic mass spectrometry sector, narrowing the gap with international competitors [161]. - The company plans to enter new markets in Europe and North America, targeting a 15% growth in these regions [185]. - The company is exploring potential acquisitions to enhance its market position, with a budget of $100 million allocated for this purpose [180]. Corporate Governance - The audit report issued by the accounting firm was a standard unqualified opinion [5]. - The company’s board of directors and supervisory board members have confirmed the authenticity and completeness of the annual report [4]. - The company has established a robust corporate governance structure, holding 13 board meetings and 12 supervisory meetings during the reporting period [170]. - All proposals at the shareholder meetings were approved without any rejections, indicating strong shareholder support [171]. - The company has implemented a new hiring strategy for core technical personnel to enhance its R&D capabilities [193]. Operational Risks and Challenges - The company has detailed various operational risks and corresponding countermeasures in the report [4]. - The company faces risks related to reliance on government subsidies, which could adversely affect profitability if funding is reduced [108]. - The company is exposed to inventory devaluation risks due to potential market changes and increased competition [106]. - The company is at risk of losing market share due to intense competition from international industry giants in the mass spectrometry market [110]. - The company’s reliance on high-end imported components poses procurement risks if there are changes in foreign manufacturers' strategies or export policies [104]. Product Development and Innovation - New product launches include the SPAMS series and SPIMS series, aimed at enhancing PM2.5 and VOCs monitoring capabilities [13]. - The company launched several new products, including a triple quadrupole liquid chromatography-mass spectrometry system and a gas chromatography-mass spectrometry system [34]. - The company has developed a rapid response liquid chromatography-quadrupole time-of-flight mass spectrometer, enhancing capabilities in life sciences and environmental monitoring [83]. - The company has successfully developed a triple quadrupole liquid mass spectrometer, marking a significant technological breakthrough in domestic manufacturing [67]. - The company is focusing on key technology breakthroughs to ensure the successful development of mass spectrometers, with total investment exceeding initial estimates [84]. Customer and Market Insights - User data indicated an increase in active users by 20% compared to the previous year, reaching a total of 500,000 active users [12]. - Customer satisfaction metrics have improved, with a reported increase of I% in positive feedback from users [178]. - The company’s products are primarily used in environmental monitoring, laboratory analysis, and healthcare sectors, reflecting a diverse application landscape [56]. Financial Management - The company reported a total investment of RMB 58,805,000 in 2022, a significant increase of 468.16% compared to RMB 10,350,000 in the previous year [141]. - The company's short-term borrowings increased by 152.91% to 184.64 million RMB, indicating a significant rise in debt levels [134]. - The company's retained earnings decreased by 32.16% to 158.72 million RMB, suggesting a decline in accumulated profits [134]. - The company has seen an increase in short-term borrowings due to expanded operational scale, indicating growth in business activities [1].

2023 年第一季度报告 证券代码：688622 证券简称：禾信仪器 广州禾信仪器股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年同 | | --- | --- | --- | | | | 期增减变动幅度 | | | | (%) | | 营业收入 | 56,915,996.54 | 26.10 | | 归属于上市公司股东的净利润 | -16,361,746.46 | 不适用 | | 归属于上市公司股东的扣除非经常 | -22,667,661.13 | 不适用 | ...

[Key Financial Data](index=1&type=section&id=Item%20I.%20Key%20Financial%20Data) [Key Accounting Data and Financial Indicators](index=1&type=section&id=Key%20Accounting%20Data%20and%20Financial%20Indicators) The company's performance significantly declined in Q3 and the first three quarters of 2022, marked by sharp revenue decrease, net profit turning to loss, and substantial R&D investment Key Financial Indicators for Q1-Q3 2022 | Indicator | Year-to-Date (2022 Q1-Q3) (RMB) | Prior Period (2021 Q1-Q3) (RMB) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 150,909,898.71 | 240,696,767.81 | -37.30% | | Net Profit Attributable to Parent Company Shareholders | -43,820,669.08 | 39,288,298.33 | -211.54% | | Net Profit Attributable to Parent Company Shareholders Excluding Non-recurring Gains and Losses | -67,340,742.97 | 17,189,352.86 | -491.76% | | Net Cash Flow from Operating Activities | -83,509,479.68 | -61,168,444.46 | Not Applicable | | Basic Earnings Per Share (RMB/share) | -0.63 | 0.75 | -184.00% | | Total R&D Expenses | 52,476,192.85 | 32,648,604.01 | 60.73% | Key Financial Indicators for Q3 2022 | Indicator | Current Period (2022 Q3) (RMB) | Prior Period (2021 Q3) (RMB) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 41,503,318.95 | 112,560,149.98 | -63.13% | | Net Profit Attributable to Parent Company Shareholders | -26,832,165.96 | 24,532,522.71 | -209.37% | | Total R&D Expenses | 21,257,190.25 | 12,427,982.22 | 71.04% | [Non-recurring Gains and Losses Items and Amounts](index=3&type=section&id=Non-recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) In the first three quarters of 2022, the company's total non-recurring gains and losses amounted to **RMB 23.52 million**, partially offsetting operating losses, with government grants being the largest component at **RMB 26.38 million** Non-recurring Gains and Losses Items for Q1-Q3 2022 | Item | Year-to-Date Amount (RMB) | | :--- | :--- | | Gains and Losses from Disposal of Non-current Assets | 1,478,395.15 | | Government Grants Included in Current Profit and Loss | 26,376,027.05 | | Gains and Losses from Entrusted Investment or Asset Management | 1,375,659.49 | | Other Non-operating Income and Expenses | -380,953.78 | | **Total** | **23,520,073.89** | [Analysis of Changes in Key Financial Indicators](index=5&type=section&id=Analysis%20of%20Changes%20in%20Key%20Accounting%20Data%2C%20Financial%20Indicators%20and%20Reasons) The company explained significant changes in key financial indicators, attributing revenue and net profit declines primarily to pandemic-induced order delays, while increased R&D investment reflects a strategic choice to expand product lines and new product development - The primary reason for the year-on-year decrease in operating revenue is the delay in order acquisition due to the pandemic[11](index=11&type=chunk) - Key reasons for the significant decline in net profit include: 1) decreased operating revenue; 2) increased investment in new product R&D to enrich product lines; and 3) increased selling expenses due to market expansion efforts[11](index=11&type=chunk) - The substantial year-on-year increase in R&D investment is primarily due to higher R&D personnel salaries and material expenditures aimed at enriching product lines and investing in new products[12](index=12&type=chunk) [Shareholder Information](index=6&type=section&id=Item%20II.%20Shareholder%20Information) [Shareholding Status](index=6&type=section&id=Total%20Number%20of%20Common%20Shareholders%20and%20Preferred%20Shareholders%20with%20Restored%20Voting%20Rights%20and%20Shareholding%20of%20Top%20Ten%20Shareholders) As of September 30, 2022, the company had 4,129 common shareholders, with a relatively concentrated equity structure where the top two shareholders, Zhou Zhen and Fu Zhong, acting in concert, collectively hold over **34%** of shares, and the top ten include several state-owned legal entities and investment institutions - As of the end of the reporting period, the company had **4,129** common shareholders[14](index=14&type=chunk) Shareholding Status of Top Five Shareholders | Shareholder Name | Shareholding Percentage (%) | Number of Shares Held (shares) | Shareholder Type | | :--- | :--- | :--- | :--- | | Zhou Zhen | 20.87 | 14,609,675 | Domestic Individual | | Fu Zhong | 13.52 | 9,465,447 | Domestic Individual | | Kunshan Guoke Venture Capital Co., Ltd. | 9.96 | 6,968,636 | State-owned Legal Person | | Gongqingcheng Tongce Investment Management Partnership | 8.63 | 6,040,000 | Other | | Yingfutaike Venture Capital Co., Ltd. | 6.64 | 4,645,760 | Domestic Non-state-owned Legal Person | - The company's controlling shareholders and actual controllers, Zhou Zhen and Fu Zhong, are concerted parties; additionally, Zhou Zhen effectively controls Gongqingcheng Tongce Investment Management Partnership[16](index=16&type=chunk) [Other Reminders](index=8&type=section&id=Item%20III.%20Other%20Reminders) [Other Important Information](index=8&type=section&id=Other%20Important%20Information%20Regarding%20the%20Company%27s%20Operating%20Performance%20During%20the%20Reporting%20Period%20Requiring%20Investor%20Attention) The company confirms no other significant operating information requires special investor attention during the reporting period - The company has no other important operating information requiring investor attention during the reporting period[17](index=17&type=chunk) [Quarterly Financial Statements](index=9&type=section&id=Item%20IV.%20Quarterly%20Financial%20Statements) [Consolidated Balance Sheet](index=9&type=section&id=Consolidated%20Balance%20Sheet) As of September 30, 2022, total assets were **RMB 871 million**, a **6.45%** decrease from year-end, mainly due to reduced cash; total liabilities were **RMB 335 million**, largely unchanged; and total equity attributable to parent company shareholders was **RMB 550 million**, down **9.15%** Key Items from Consolidated Balance Sheet | Item | September 30, 2022 (RMB) | December 31, 2021 (RMB) | Change (%) | | :--- | :--- | :--- | :--- | | Total Assets | 871,274,898.96 | 931,395,210.90 | -6.45% | | Cash and Cash Equivalents | 180,829,289.70 | 340,149,091.93 | -46.84% | | Total Liabilities | 335,085,757.18 | 338,112,699.44 | -0.90% | | Total Equity Attributable to Parent Company Shareholders | 549,779,329.11 | 605,122,842.16 | -9.15% | [Consolidated Income Statement](index=11&type=section&id=Consolidated%20Income%20Statement) In the first three quarters of 2022, operating revenue was **RMB 151 million**, a **37.30%** year-on-year decrease, leading to a **RMB 43.82 million** loss from a **RMB 39.29 million** profit in the prior period, driven by revenue decline and significant increases in selling and R&D expenses Key Items from Consolidated Income Statement (Q1-Q3 2022) | Item | Jan-Sep 2022 (RMB) | Jan-Sep 2021 (RMB) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 150,909,898.71 | 240,696,767.81 | -37.30% | | Operating Cost | 63,773,953.57 | 103,889,438.25 | -38.61% | | Selling Expenses | 82,357,964.70 | 56,957,235.53 | 44.60% | | R&D Expenses | 52,476,192.85 | 32,648,604.01 | 60.73% | | Net Profit Attributable to Parent Company Shareholders | -43,820,669.08 | 39,288,298.33 | -211.54% | [Consolidated Cash Flow Statement](index=14&type=section&id=Consolidated%20Cash%20Flow%20Statement) In the first three quarters of 2022, net cash outflow from operating activities increased to **RMB 83.51 million** due to reduced sales receipts and increased expenses, while investing activities had a net outflow of **RMB 98.99 million** and financing activities a net inflow of **RMB 23.16 million**, leading to a significant decrease in period-end cash and cash equivalents Key Items from Consolidated Cash Flow Statement (Q1-Q3 2022) | Item | Jan-Sep 2022 (RMB) | Jan-Sep 2021 (RMB) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | -83,509,479.68 | -61,168,444.46 | | Net Cash Flow from Investing Activities | -98,986,276.22 | -101,195,837.27 | | Net Cash Flow from Financing Activities | 23,155,178.25 | 332,762,702.78 | | Net Increase in Cash and Cash Equivalents | -159,340,577.65 | 170,398,421.05 |

Financial Performance - The company reported a revenue of RMB 100 million for the first half of 2022, representing a year-on-year increase of 15%[1] - The company's operating revenue for the first half of 2022 was ¥109,406,579.76, a decrease of 14.62% compared to ¥128,136,617.83 in the same period last year[19] - The net profit attributable to shareholders of the listed company was -¥16,988,503.12, representing a decline of 215.13% from ¥14,755,775.62 in the previous year[19] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥31,180,803.73, a significant drop of 2,071.74% compared to ¥1,581,384.45 in the same period last year[19] - The net cash flow from operating activities was -¥66,672,411.09, worsening from -¥50,066,530.43 in the previous year[19] - The total assets at the end of the reporting period were ¥846,671,715.74, a decrease of 9.10% from ¥931,395,210.90 at the end of the previous year[19] - The net assets attributable to shareholders of the listed company were ¥576,353,245.99, down 4.75% from ¥605,122,842.16 at the end of the previous year[19] - Basic earnings per share for the reporting period is -0.24 CNY, a decrease of 185.71% compared to the same period last year[20] - The weighted average return on equity decreased by 8.58 percentage points to -2.86%[20] Revenue Projections and Growth - The company expects a revenue growth of 10% to 15% for the second half of 2022, projecting total revenue between RMB 110 million and RMB 115 million[1] - New product launches are anticipated to contribute an additional RMB 20 million in revenue by the end of 2022[1] - The company is expanding its market presence in Southeast Asia, targeting a 25% market share in the region by 2025[1] Research and Development - Research and development expenses increased by 30% to RMB 15 million, focusing on innovative technologies and product enhancements[1] - R&D expenditure accounted for 28.53% of operating revenue, an increase of 12.75 percentage points year-on-year[21] - The total R&D expenditure for the period was ¥31,219,002.60, representing a 54.39% increase compared to ¥20,220,621.79 in the same period last year[45] - The company has a total of 411 intellectual property applications, with 234 granted, including 76 software copyrights[43] - The company applied for 9 new domestic invention patents during the reporting period, of which 3 were granted, bringing the total to 45 granted invention patents[43] - The company is currently developing high-stability high-frequency power supplies and automated sample processing systems, with a total investment of ¥10,000,000 for the project[48] - A project aimed at developing high-resolution mass spectrometry has received ¥22,800,000 in total investment, with ongoing testing and verification[48] - The company has completed a project for a portable gas chromatography-mass spectrometry system, with an investment of ¥7,500,000, which is now ready for market[48] Market and Competitive Landscape - The global mass spectrometer market is highly concentrated, primarily dominated by international giants such as Waters, Danaher, and Agilent, with North America holding the largest market share[35] - In the first half of 2022, China imported 7,173 mass spectrometers, indicating a high reliance on foreign high-end products[36] - The Chinese government has introduced multiple policies to support the development of domestic high-end analytical instruments, signaling positive growth for the mass spectrometer industry[38] - The company focuses on high-end mass spectrometer R&D, production, and sales, achieving strong brand advantages in PM2.5, VOCs, and O3 monitoring within the atmospheric environment monitoring sector[39] Risks and Challenges - The company has identified potential risks related to supply chain disruptions and is implementing measures to mitigate these risks[1] - The company faced risks related to core competitiveness, including potential R&D failures and technology updates, which could adversely affect its sustainable development[65][68] - The company is exposed to risks from concentrated downstream application fields, particularly in atmospheric environmental monitoring, which is its main revenue source[70] - The company is at risk of inventory depreciation due to slow turnover and potential market demand changes, which could lead to unsold products[73] Employee and Compensation - The number of R&D personnel increased to 161, accounting for 21.16% of the total workforce, up from 20.06% in the same period last year[52] - The average salary of R&D personnel rose to 11.84 million RMB, compared to 8.92 million RMB in the previous year, indicating a focus on attracting and retaining talent[52] - The company reported an increase in employee compensation expenses due to an increase in personnel scale[85] Environmental and Social Responsibility - The company is actively engaged in carbon emission reduction strategies, including consulting services and monitoring systems, to support national carbon neutrality goals[101] - The company has implemented energy-saving measures, such as paperless office processes, to reduce resource consumption and greenhouse gas emissions[102] - The company has established a comprehensive carbon monitoring and assessment system to support its environmental initiatives[101] Shareholder Commitments and Governance - The company has committed to strict adherence to share lock-up agreements, with any unfulfilled commitments resulting in the forfeiture of corresponding gains[110] - The commitments made by shareholders are aimed at maintaining market stability and protecting the interests of all investors[137][140] - The company emphasizes compliance with the laws and regulations regarding share reduction and information disclosure[139][141] - The company will implement measures to minimize investor losses if commitments are not met due to force majeure[199]

Financial Performance - The company's operating revenue for Q1 2022 was ¥45,134,456.52, representing a decrease of 9.26% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥12,333,292.83, a significant decline of 1,358.63% year-over-year[5]. - The basic earnings per share were -¥0.18, reflecting a decrease of 980.98% year-over-year[6]. - Operating profit for Q1 2022 was CNY -13,035,669.75, compared to CNY 607,875.95 in Q1 2021, indicating a significant decline[18]. - Net profit attributable to shareholders for Q1 2022 was CNY -12,333,292.83, compared to CNY 979,900.05 in Q1 2021[19]. - The net profit for Q1 2022 was a loss of CNY 11,247,405.33, compared to a net profit of CNY 8,296,083.35 in Q1 2021[27]. Research and Development - The total R&D investment amounted to ¥15,689,155.11, an increase of 74.76% compared to the previous year, accounting for 34.76% of operating revenue[6]. - Research and development expenses increased to CNY 15,689,155.11 in Q1 2022, up from CNY 6,322,622.74 in Q1 2021, reflecting a 148% increase[18]. - The company's research and development expenses increased significantly to CNY 11,912,986.57 in Q1 2022, compared to CNY 4,324,349.89 in Q1 2021, reflecting a focus on innovation[26]. Cash Flow and Liquidity - The net cash flow from operating activities was -¥80,054,513.03, with no applicable year-over-year comparison[5]. - Cash flow from operating activities for Q1 2022 was CNY -80,054,513.03, worsening from CNY -51,119,247.92 in Q1 2021[21]. - Cash flow from investing activities showed a net outflow of CNY -70,873,415.29 in Q1 2022, compared to CNY -18,056,931.00 in Q1 2021[22]. - Cash flow from operating activities showed a net outflow of CNY 64,519,478.16 in Q1 2022, compared to a net outflow of CNY 45,848,483.27 in Q1 2021[29]. - The net cash flow from investment activities was -$85,888,400, compared to -$14,996,419.23 in the previous year[30]. - The net cash flow from financing activities was -$1,332,393.37, contrasting with a positive $33,685,449.16 in the previous year[30]. - The ending cash and cash equivalents balance was $138,101,020.44, down from $91,713,890.53 year-over-year[30]. Assets and Liabilities - Total assets at the end of the reporting period were ¥845,143,201.99, a decrease of 9.26% from the end of the previous year[6]. - Current assets totaled CNY 562,274,547.91, down from CNY 650,785,057.03, indicating a decrease of about 13.56%[15]. - Total liabilities decreased to CNY 263,550,229.34 in Q1 2022 from CNY 338,112,699.44 in Q1 2021[18]. - The total equity attributable to shareholders was CNY 592,893,812.92 in Q1 2022, down from CNY 605,122,842.16 in Q1 2021[18]. - The total assets decreased to CNY 944,188,513.67 as of March 31, 2022, down from CNY 1,011,166,085.46 at the end of 2021[24]. - The total liabilities decreased to CNY 313,355,048.93 in Q1 2022, down from CNY 369,189,478.98 in Q1 2021[25]. Shareholder Structure and Strategic Initiatives - The company has a significant shareholder structure, with the top three shareholders holding a combined 44.35% of shares[11]. - The company is actively involved in strategic partnerships and investments, as indicated by the presence of various investment funds among its major shareholders[12]. Audit and Reporting - The report indicates no significant changes in the audit opinion type, maintaining a consistent approach in financial reporting[13]. - The company did not apply the new accounting standards starting from 2022[30].

Financial Performance - The proposed cash dividend for 2021 is CNY 1.7 per 10 shares, totaling CNY 11,899,593.02 (including tax), which represents 15.14% of the net profit attributable to shareholders of the parent company[5]. - The company's operating revenue for 2021 was CNY 464,237,256.58, representing a 48.66% increase compared to CNY 312,272,106.42 in 2020[23]. - The net profit attributable to shareholders for 2021 was CNY 78,574,746.75, a 13.13% increase from CNY 69,453,951.06 in 2020[23]. - The net profit after deducting non-recurring gains and losses was CNY 44,330,006.80, showing a decrease of 14.29% from CNY 51,719,010.62 in 2020[23]. - The net cash flow from operating activities decreased by 76.71% to CNY 14,928,899.58 from CNY 64,087,116.55 in 2020[23]. - The total assets at the end of 2021 were CNY 931,395,210.90, a 69.35% increase from CNY 549,979,328.90 at the end of 2020[23]. - The net assets attributable to shareholders increased by 141.45% to CNY 605,122,842.16 from CNY 250,624,681.24 in 2020[23]. - The basic earnings per share for 2021 were CNY 1.38, a 4.55% increase from CNY 1.32 in 2020[24]. - The diluted earnings per share for 2021 were also CNY 1.38, consistent with the basic earnings per share[24]. Research and Development - Research and development (R&D) investment reached RMB 53,219,249.98, a year-on-year increase of 36.56%[35]. - The R&D expenditure as a percentage of operating revenue was 11.46%, down by 1.02 percentage points from 12.48% in 2020[24]. - The company expanded its R&D team to 167 personnel, representing 21.19% of the total workforce[35]. - The company has applied for 50 new patents, including 35 invention patents and 15 utility model patents, enhancing its intellectual property portfolio[35]. - The company has achieved significant advancements in core technologies, maintaining a leading position in domestic development across various applications, including environmental monitoring and food safety[64]. - The company has not capitalized any R&D expenditures, maintaining a focus on immediate operational needs[70]. - The company is committed to independent innovation and the localization of high-end mass spectrometers, competing against international giants in the industry[58]. Market and Competitive Landscape - The company focuses on high-end mass spectrometers, with significant market potential in healthcare, food safety, and environmental monitoring, driven by increasing government investment and public concern[55]. - The domestic mass spectrometer market is primarily dominated by foreign products, with high-end mass spectrometers mainly relying on imports, which limits the effective exploration of potential user demand in various industries[135]. - The company aims to enhance its core competitiveness and market share in domestic mass spectrometers by expanding into air quality monitoring, water quality monitoring, medical health, and food safety applications[138]. - The company is exposed to competition in the environmental monitoring field, which may pressure product pricing and profit margins[93]. Governance and Compliance - The company has established a robust corporate governance structure, holding multiple board meetings and ensuring effective decision-making processes[144]. - The company did not have any dissenting opinions from board members regarding company matters during the reporting period[172]. - The company is committed to maintaining compliance with regulatory requirements as outlined by the Company Law and the China Securities Regulatory Commission[173]. - The audit committee's responsibilities included reviewing financial reports and internal audit plans, ensuring transparency and accountability[174]. Strategic Initiatives - The company plans to enhance R&D efforts and expand product applications to compete with international giants in the mass spectrometry market[134]. - The company plans to continue the development and industrialization of new products, including automatic microbial detection mass spectrometers and triple quadrupole mass spectrometers, to meet increasing market demands[139]. - The company is committed to improving its service and technical support systems, which are becoming critical factors for customers when selecting mass spectrometers[136]. - The company plans to enhance its digital marketing strategy, allocating an additional 5% of revenue towards online advertising in 2022[155]. Employee and Labor Management - The total number of employees in the parent company and major subsidiaries is 788, with 335 in technical roles and 167 in research and development[180]. - The company emphasizes employee training and development, aiming to enhance skills and career growth through various training programs[182]. - Total remuneration for all directors, supervisors, and senior management was CNY 4.6004 million[166]. Environmental and Social Responsibility - The company emphasizes ESG practices, focusing on environmental protection, social responsibility, and corporate governance to achieve high-quality development[194]. - The company has not faced any administrative penalties related to environmental issues during the reporting period, complying with national and local environmental protection requirements[198]. - The company actively manages resource consumption, implementing measures to reduce energy and water usage in production and operations[200].

Financial Performance - The company's operating revenue for Q3 2021 was ¥112,560,149.98, representing a year-on-year increase of 36.29%[5] - The net profit attributable to shareholders for Q3 2021 was ¥24,532,522.71, reflecting a year-on-year increase of 14.49%[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥15,607,968.41, showing a decrease of 10.60% compared to the same period last year[5] - The basic and diluted earnings per share for Q3 2021 were both ¥0.47, an increase of 14.49% year-on-year[6] - The total operating revenue for the first three quarters of 2021 reached ¥240,696,767.81, a significant increase of 50.94% compared to ¥159,362,721.95 in the same period of 2020[19] - The net profit attributable to the parent company's shareholders was ¥39,288,298.33, an increase of 30.5% from ¥30,087,156.97 in the same period last year[21] - The basic earnings per share for the current period was ¥0.75, compared to ¥0.57 in the previous year, representing a growth of 31.6%[22] Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,004,846,659.20, marking an increase of 82.71% compared to the end of the previous year[6] - The total liabilities increased to ¥448,761,682.79 from ¥303,454,522.08, which is a rise of 48%[17] - Non-current assets totaled ¥231,577,247.59, up from ¥154,071,860.23, marking an increase of 50.3%[17] - Total assets reached ¥1,004,846,659.20, compared to ¥549,979,328.90, reflecting a growth of 82.5%[17] - Total current assets reached RMB 773,269,411.61, up from RMB 395,907,468.67 year-over-year[15] - The company reported a deferred income of 31,879,604.08, indicating future revenue recognition[29] - The long-term payables were recorded at 2,750,000.00, reflecting the company's long-term financial commitments[29] Shareholder Information - The equity attributable to shareholders at the end of the reporting period was ¥563,511,683.58, an increase of 124.84% year-on-year[6] - The total number of ordinary shares at the end of the reporting period was 3,921[12] - The largest shareholder, Zhou Zhen, holds 14,609,675 shares, representing 20.87% of total shares[12] - The total number of shareholders was not specified, but the top ten shareholders hold a significant portion of the company[12] Research and Development - Research and development expenses totaled ¥12,427,982.22, which accounted for 11.04% of operating revenue, an increase of 0.19 percentage points from the previous year[6] - The company reported a significant increase in research and development expenses, which rose to ¥30,663,377.86 from ¥22,390,343.44, a growth of 37%[20] - The company has increased its investment in R&D projects, with material costs for R&D rising approximately 65% year-on-year and employee compensation for R&D staff increasing by 30.3%[10] Cash Flow and Investments - Operating cash inflow for the first three quarters of 2021 reached CNY 333.75 million, a 70.4% increase from CNY 195.89 million in the same period of 2020[24] - Net cash outflow from operating activities was CNY -61.17 million, compared to CNY -39.28 million in the previous year, indicating a worsening cash flow situation[25] - Cash and cash equivalents at the end of Q3 2021 totaled CNY 336.79 million, significantly up from CNY 82.74 million at the end of Q3 2020[26] - The company raised CNY 285.68 million from investment activities in 2021, compared to no funds raised in the same period of 2020[25] - Cash outflow from investment activities was CNY 152.35 million, down from CNY 183.62 million in the previous year, indicating reduced investment spending[25] - Financing activities generated a net cash inflow of CNY 332.76 million, a significant increase from CNY 43.57 million in the same period of 2020[25] Operational Insights - The company reported a significant increase in hardware sales, which grew by 61% year-on-year, contributing to overall revenue growth[10] - The company has not disclosed any new product developments or market expansion strategies in the current report[14] - There are no significant reminders or additional important information regarding the company's operational situation during the reporting period[14] - The company has plans for market expansion and new product development, although specific details were not disclosed in the report[18]

Financial Performance - The company's operating revenue for Q3 2021 was ¥112,560,149.98, representing a year-on-year increase of 36.29%[5] - The net profit attributable to shareholders was ¥24,532,522.71, reflecting a growth of 14.49% compared to the same period last year[5] - The basic earnings per share for the quarter was ¥0.47, an increase of 14.49% year-on-year[6] - Total revenue for the first three quarters of 2021 reached ¥240,696,767.81, a significant increase of 50.94% compared to ¥159,362,721.95 in the same period of 2020[22] - Net profit for the third quarter of 2021 was ¥33,443,081.89, representing a 17.73% increase from ¥28,437,556.90 in the same quarter of 2020[23] - The company reported a total of ¥39,288,298.33 in net profit attributable to shareholders for the third quarter of 2021, compared to ¥30,087,156.97 in the same quarter of 2020, indicating a growth of 30.54%[24] Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,004,846,659.20, up 82.71% from the end of the previous year[6] - As of September 30, 2021, the company's total current assets reached ¥773,269,411.61, a significant increase from ¥395,907,468.67 on December 31, 2020, representing an increase of approximately 95.4%[17] - Total assets as of the end of the third quarter of 2021 amounted to ¥1,004,846,659.20, up from ¥549,979,328.90 at the end of the third quarter of 2020, marking an increase of 82.43%[19] - Total liabilities reached ¥448,761,682.79, an increase of 47.83% from ¥303,454,522.08 in the previous year[19] - The company's total assets as of September 30, 2021, were CNY 549,979,328.90, a decrease from CNY 552,922,703.45 at the beginning of the year[29] - Total liabilities amounted to CNY 303,454,522.08, down from CNY 306,397,896.63 at the beginning of the year[30] Cash Flow - The company reported a cash flow from operating activities of -¥61,168,444.46 for the year-to-date[5] - In the first three quarters of 2021, the company generated cash inflows from operating activities amounting to CNY 333,754,603.19, a 70.4% increase compared to CNY 195,893,878.96 in the same period of 2020[25] - The net cash flow from operating activities for the first three quarters of 2021 was -CNY 61,168,444.46, worsening from -CNY 39,283,719.49 in the previous year[25] - Cash inflows from investment activities totaled CNY 51,152,632.59, down 61.4% from CNY 132,480,393.72 in the same period of 2020[26] - The net cash flow from investment activities was -CNY 101,195,837.27, compared to -CNY 51,137,420.36 in the previous year, indicating increased cash outflows[26] - The net cash flow from financing activities was CNY 332,762,702.78, compared to CNY 43,574,663.39 in the previous year, showing a substantial improvement[26] Research and Development - Research and development expenses totaled ¥12,427,982.22, which is 11.04% of operating revenue, marking an increase of 0.19 percentage points[6] - The company experienced a 61% increase in hardware sales year-on-year, contributing to overall revenue growth[10] - R&D material costs increased by approximately 65%, and the number of R&D personnel grew, leading to a 30.3% rise in employee compensation[10] - Research and development expenses for the third quarter of 2021 were ¥30,663,377.86, an increase of 37.06% compared to ¥22,390,343.44 in the same quarter of 2020[23] Equity and Reserves - Shareholders' equity totaled ¥556,084,976.41, up 125.66% from ¥246,524,806.82 in the same period of 2020[19] - Total equity attributable to shareholders reached ¥250,624,681.24, reflecting a strong financial position[31] - Unallocated profits amounted to ¥164,978,459.91, indicating retained earnings for future growth[31] - Capital reserve was recorded at ¥15,675,512.61, contributing to the company's equity base[31] - Surplus reserve totaled ¥17,473,102.72, indicating a buffer for future contingencies[31] - The financial report reflects a stable equity structure, essential for investor confidence[31] Future Outlook - The company has not disclosed any new product launches or technological advancements in the current report[15] - Future outlook and performance guidance were not explicitly mentioned in the provided documents, indicating a need for further clarification in subsequent communications[15]